Sept. 20, 2012
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that a poster on its oral prostate cancer vaccine candidate, AEZS-120, will be on display at the upcoming 32
Congress of the
Société Internationale d'Urologie
which will be held
September 30 through October 4, 2012
International Congress Center in
The abstract #839 titled, "
Pre-Clinical Proof of Concept and Characterization of AEZS-120, a Therapeutic Oral Prostate Cancer Vaccine Candidate Based on Live Recombinant Attenuated Salmonella
", J. Fensterle, B. Bergmann, M. Teifel, J. Engel, T. Rudel, W. Goebel, U. Rapp, underlines the feasibility of an oral therapeutic vaccination approach against prostate cancer. The safety pharmacology and toxicology experiments suggest that the profile of AEZS-120 is similar to the approved carrier strain and, therefore, pave the way for Phase 1 clinical testing.
AEZS-120 is a live recombinant oral tumor vaccine candidate based on
Ty21a as a carrier strain.
Ty21a is an approved oral typhoid vaccine which has been safely applied in more than 350 million doses. The principle of AEZS-120 is based on the recombinant expression of prostate specific antigen fused to the B subunit of cholera toxin and a secretion signal in the presence of the
type I hemolysin secretion system. The proprietary system allows the secretion of the antigen together with an immunological adjuvant which has been demonstrated to be required for optimal induction of CD8 T-cell responses by recombinant
based bacterial vaccines. The proof-of-concept was already demonstrated for the mouse homologue of AEZS-120 in a mouse tumor-challenge model.
In general, by varying the antigen and/or the carrier, this proprietary platform technology is suitable for virtually any therapeutic or prophylactic vaccine indication with a relatively favorable cost of goods expectation in large scale.